poisar

Stocks · News reference

Truist Securities Maintains Buy on Boston Scientific, Lowers Price Target to $51

Benzinga Newsdesk

Truist Securities analyst Richard Newitter maintains Boston Scientific (NYSE:BSX) with a Buy and lowers the price target from $57 to $51.

More stocks newsConnected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

BSX
Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Researchandmarkets.Com

    China Adult Feeding Tubes and Formula Market Outlook to 2033 - Revenue, Volume, Pricing, and Company Share | Forecast Data Reveals Market Entry and Expansion Opportunities

    ResearchAndMarkets.com released a comprehensive market report on China's adult feeding tubes and formula market through 2033, providing revenue, volume, and pricing forecasts. The report analyzes two main segments (Adult Feeding Tubes and Adult Feeding Formula) and includes competitive landscape data with 2025 company share information for key market participants.

    NSRGYABTBSX
  3. SEC EDGAR

    8-K filing — BOSTON SCIENTIFIC CORP (BSX)

    Filed: 2026-10-07 AccNo: 0000885725-26-000064 Size: 292 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits

    BSX